Welcome to our dedicated page for Cigna Group SEC filings (Ticker: CI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cigna Group (NYSE: CI) files a broad range of documents with the U.S. Securities and Exchange Commission that together provide a detailed view of its operations as a global health company. These SEC filings cover its activities across Cigna Healthcare and Evernorth Health Services, including health insurance, pharmacy benefit services, specialty pharmacy, care services, and related health solutions.
On this page, you can review current and historical 10-K and 10-Q reports to understand how The Cigna Group describes its business segments, risk factors, and financial performance over time. These filings typically break out results for Evernorth Health Services, Cigna Healthcare, and Corporate and Other Operations, and they explain non-GAAP measures such as adjusted income from operations that management uses to evaluate underlying trends.
The Cigna Group also submits frequent Form 8-K reports. Recent examples include 8-K filings announcing quarterly earnings results, affirmations of full-year outlook, changes to Board committee structures, Board appointments and retirements, and the issuance of senior notes with details on interest rates, maturities, and intended use of proceeds. These current reports highlight material events such as capital markets transactions and governance changes.
Debt offerings and related agreements are documented through exhibits to 8-K filings, including underwriting agreements, supplemental indentures, and legal opinions. These materials outline the terms of senior notes and the covenants that apply to The Cigna Group’s indebtedness.
Using this page, you can access real-time updates from EDGAR alongside AI-powered summaries that explain the key points of lengthy filings in plain language. AI analysis can help you quickly identify segment performance drivers in 10-Qs and 10-Ks, interpret the implications of new debt issuances, and understand governance or committee changes disclosed in 8-Ks. You can also review any Form 4 insider transaction reports, when available, to see how directors and executives are trading CI shares.
For investors, analysts, and researchers, The Cigna Group’s SEC filings provide a structured record of its financial condition, strategic initiatives, risk disclosures, and corporate governance framework, and this page brings those documents together with tools to make them easier to interpret.
The Cigna Group EVP and General Counsel Andrea L. Nelson filed an initial ownership report showing existing stock and option holdings in Cigna Group common shares. This Form 3 does not report new buying or selling activity; it lists current positions.
Nelson holds 3,840 shares of common stock directly, plus 72.0769 shares indirectly through The Cigna Group’s 401(k) Plan. She also holds several employee stock options to buy common stock, with exercise prices ranging from $227.0200 to $336.4750 per share and expiration dates from 2032 to 2036. The options cover 453, 1,263, 1,090, 2,032, and 1,829 underlying shares, and each grant vests in three equal annual installments beginning on the dates specified in the footnotes.
The Vanguard Group filed Amendment No. 8 to a Schedule 13G/A for Cigna Group common stock stating it beneficially owns 0 shares, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026 that disaggregated certain subsidiaries' holdings and directs those subsidiaries to report separately “in accordance with SEC Release No. 34-39538 (January 12, 1998).” The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
The Cigna Group is seeking shareholder votes at its 2026 virtual annual meeting on April 22, 2026, including electing 12 directors, approving executive pay, ratifying PricewaterhouseCoopers and considering a shareholder written-consent proposal.
For 2025, Cigna reports revenue of $275 billion, up 11%, shareholders’ net income of $6 billion ($22.18 per share), adjusted income from operations of $8 billion ($29.84 per share), operating cash flow of $9.6 billion and $5.2 billion returned via dividends and buybacks. The company invested $3.5 billion in Shields Health Solutions and completed a $4.9 billion sale of Medicare-related businesses, sharpening focus on higher‑growth health services. The proxy also details a planned CEO transition from David Cordani to Brian Evanko on July 1, 2026, an Executive Chair role for Cordani, a strengthened Lead Independent Director role, and extensive governance, sustainability and pay‑for‑performance practices.
Cigna Group disclosed that The Vanguard Group filed an amendment to its Schedule 13G reporting beneficial ownership of 26,445,689 shares of common stock, representing 10.03% of the class.
The filing shows shared voting power of 2,785,837 shares and shared dispositive power over 26,445,689 shares. The filer notes an internal realignment effective January 12, 2026 that will lead certain Vanguard subsidiaries to report beneficial ownership separately.
Cigna Group Chief Accounting Officer Jamie G. Kates reported equity compensation changes. On February 27, 2026, Kates was granted 657 employee stock options and additional shares of common stock as part of strategic performance share settlements and new restricted share awards. The options and restricted shares vest in three equal annual installments beginning March 1, 2027. A total of 71 and 61 shares of common stock were withheld to satisfy tax obligations tied to these awards, leaving Kates with 2,368 common shares directly owned.
Cigna Group executive Durga Prasad Koka reported new equity awards and related tax share withholdings. On February 27, 2026, he was granted an employee stock option for 4,127 shares at a price of $0.00 per share, which vests in three equal annual installments beginning March 1, 2027. He also acquired common stock through settlement of strategic performance shares for the 2023–2025 period and through restricted share grants, with vesting for certain restricted shares also starting March 1, 2027. Separate transactions show small blocks of common stock withheld at $287.55 per share to cover tax obligations on these equity awards, rather than open-market sales.
Cigna Group executive Neville Everett reported several equity transactions involving company stock. On March 2, he completed an open-market sale of 1,719 common shares at a price of $288.91 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2025.
On February 27, he received equity awards tied to company performance and compensation programs, including 2,602 and 2,678 common shares granted at no cost and 4,127 employee stock options that vest in three equal annual installments beginning March 1, 2027. Some common shares (883 and 517) were withheld to cover tax obligations upon settlement of strategic performance shares and vesting of restricted shares.
Cigna Group executive Nicole S. Jones reported a mix of stock transactions. She sold 2,307 shares of common stock at $288.91 per share in an open-market sale executed under a Rule 10b5-1 trading plan adopted on May 8, 2025.
Earlier on February 27, 2026, she received 8,066 employee stock options and 9,367 shares of common stock through equity awards and performance share settlement at no cash cost. On the same date, 2,738 shares were withheld to cover tax obligations tied to those awards.
After these transactions, she directly held 32,647 shares of Cigna common stock and 8,066 stock options, and indirectly held 1,434.7897 shares through participation in The Cigna Group’s 401(k) Plan.
Cigna Group executive Brian C. Evanko reported multiple equity compensation transactions. He received an employee stock option for 15,082 shares and two grants of common stock for 6,428 and 9,787 shares on February 27, 2026, tied to strategic performance shares and restricted stock awards.
The filing also shows dispositions of 2,979 and 1,788 common shares at $287.55 per share, which were withheld to satisfy tax obligations rather than open-market sales. Evanko additionally reports indirect holdings of common stock through a grantor retained annuity trust and The Cigna Group’s 401(k) plan.